Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab-Reference-Cited by-同舟云学术

Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab

Published:2022-11 Issue: Volume:Volume 14 Page:3293-3302
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Suzuki Shinsuke^ORCID,Abe Tomoe,Endo Tentaro,Kaya Haruka,Kitabayashi Takuro,Kawasaki Yohei,Yamada Takechiyo

Publisher

Informa UK Limited

Subject

Oncology

Reference36 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Head and neck cancer

3. Treatment choice for locally advanced head and neck cancers on the basis of risk factors: biological risk factors

4. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

5. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab;Acta Oncologica;2024-08-11

2. Serum Albumin as an Independent Predictor of Long-Term Survival in Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab;Journal of Clinical Medicine;2024-04-23

3. Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study;Anticancer Research;2024-03-27

4. Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma;Oral Oncology;2024-02

5. Eosinophil may be a predictor of immune‐related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study;Cancer Medicine;2023-11-21